Literature DB >> 15716212

Re: Weckermann D, Harzmann R. Hormone therapy in prostate cancer: LHRH antagonists versus LHRH analogues. Eur Urol 2004;46:279-84.

Philip Weston, Bo-Eric Persson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15716212     DOI： 10.1016/j.eururo.2004.11.015

Source DB:  PubMed          Journal:  Eur Urol        ISSN： 0302-2838            Impact factor:   20.096


× No keyword cloud information.
  4 in total

Review 1.  Degarelix versus luteinizing hormone-releasing hormone agonists for the treatment of prostate cancer.

Authors:  Timothy N Clinton; Solomon L Woldu; Ganesh V Raj
Journal:  Expert Opin Pharmacother       Date:  2017-05-19       Impact factor: 3.889

2.  Treatment patterns and trends in patients dying of prostate cancer in Quebec: a population-based study.

Authors:  A Dragomir; J Rocha; M Vanhuyse; F L Cury; W Kassouf; J Hu; A G Aprikian
Journal:  Curr Oncol       Date:  2017-08-31       Impact factor: 3.677

3.  Drug costs in the management of metastatic castration-resistant prostate cancer in Canada.

Authors:  Alice Dragomir; Daniela Dinea; Marie Vanhuyse; Fabio L Cury; Armen G Aprikian
Journal:  BMC Health Serv Res       Date:  2014-06-13       Impact factor: 2.655

Review 4.  Degarelix for treating advanced hormone-sensitive prostate cancer.

Authors:  Friedemann Zengerling; Joachim J Jakob; Stefanie Schmidt; Joerg J Meerpohl; Anette Blümle; Christine Schmucker; Benjamin Mayer; Frank Kunath
Journal:  Cochrane Database Syst Rev       Date:  2021-08-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.